Authorised Indian Distributor
Saxsons Group
New Delhi, India · Since 1997
High-activity I-131 capsules for thyroid cancer ablation, remnant ablation after thyroidectomy, and hyperthyroidism therapy. Available in calibrated activity levels per prescription, AERB licensed for Indian hospitals.
| Radionuclide | Iodine-131 (I-131) |
| Physical form | Oral gelatine capsule |
| Half-life | 8.02 days |
| Decay emissions | β⁻ (max 606 keV, 89%); γ 364 keV (82%) |
| Activity range | Prescription-specific; low (370 MBq) to high (7,400 MBq+) |
| Radiochemical form | Sodium iodide (NaI) in gelatin capsule |
| Radiochemical purity | ≥ 99% iodide form |
| Calibration | Activity stated at a defined reference date/time |
| Shielding | Lead pot and outer transport container per IAEA regulations |
| Stability | 14 days from calibration date (stored as directed) |
| Clinical use | Thyroid cancer ablation, remnant ablation, hyperthyroidism |
| AERB status | Licensed supply; hospital AERB authorisation required |
Radioiodine — the gold standard for thyroid disease management
Destruction of residual thyroid tissue after total thyroidectomy for differentiated thyroid cancer. Standard ablation doses 1,110–3,700 MBq depending on risk stratification.
High-dose I-131 therapy for loco-regional lymph node metastases and distant metastases in differentiated (papillary and follicular) thyroid carcinoma.
Definitive treatment for Graves' disease with calculated or fixed-activity radioiodine dose. Long-term remission with single treatment in the majority of patients.
I-131 therapy for autonomous functioning thyroid nodules and toxic multinodular goitre. Reduces goitre volume and normalises thyroid function.
Post-ablation whole-body I-131 scanning using the therapeutic dose emission. Documents complete ablation and detects occult metastatic disease.
Low-activity I-131 (< 600 MBq) for outpatient hyperthyroidism treatment where radiation protection criteria permit discharge on day of administration.
Each capsule is calibrated to the exact activity and reference time requested. Your nuclear medicine physician prescribes; the capsule arrives ready for administration — no in-house dispensing or dilution required.
I-131's β-particle (606 keV max) treats locally while the 364 keV gamma enables post-therapy whole-body scintigraphy. One radionuclide serves both the therapeutic and the imaging purpose in thyroid cancer follow-up.
Saxsons holds the required AERB import licence for I-131 therapeutic supply. Full batch documentation, transport safety data and patient administration records are provided with every order.
Contact Saxsons Group for prescription-specific I-131 supply, AERB documentation and therapy dose planning support across India.